Possible teatment for sarcopenia by inhibition of inflammation
Project/Area Number |
15K19280
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
General internal medicine(including psychosomatic medicine)
|
Research Institution | The University of Tokyo |
Principal Investigator |
|
Research Collaborator |
OGAWA Sumito 東京大学, 医学部附属病院, 准教授 (20323579)
|
Project Period (FY) |
2015-04-01 – 2017-03-31
|
Project Status |
Completed (Fiscal Year 2016)
|
Budget Amount *help |
¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
Keywords | 炎症 / サルコペニア / 筋萎縮 / HMB / ビタミンD / 補中益気湯 / 後肢懸垂モデル |
Outline of Final Research Achievements |
Sarcopenia is an aging-related debilitating condition which is characterized by progressive loss of skeletal muscle mass and strength. The mechanism of sarcopenia is not elucidated and the treatment has not been established. We examined the involvement of inflammation in inducing muscle atrophy and how this involvement was affected by HMB (a metabolite of leucine), vitamin D and TJ-41 (a traditional herbal medicine). In tail suspended mice, which is a mouse model bearing muscle atrophy, HMB and vitamin D inhibited muscle atrophy, expression of atrophy-related genes, and elevation of the serum interleukin-6 level. TJ-41 ameliorated reactive oxygen-induced damage in myoblasts by inhibiting inflammation. We conclude that anti-inflammatory effects of HMB, vitamin D and TJ-41 might be therapeutic to sarcopenia.
|
Report
(3 results)
Research Products
(3 results)